AstraZeneca drafts plan to spin off China business amid tensions
阿斯利康计划分拆中国业务单独上市
Anglo-Swedish drugmaker views listing a separate unit in Hong Kong as potential shelter from global strife
知情人士透露，阿斯利康拟分拆其中国业务为一家单独法律实体，并在香港或上海上市，以规避地缘政治影响。
AstraZeneca has drawn up plans to break out its China business and list it separately in Hong Kong as a way to shelter the company against mounting geopolitical tensions. The Anglo-Swedish drugmaker began discussing the idea with bankers several months ago and is among a growing number of multinational companies now considering that option, according to three people familiar with the talks.
阿斯利康(AstraZeneca)已拟定计划，分拆其中国业务并在香港单独上市，以规避日益加剧的地缘政治紧张局势影响。
A separation might not ultimately take place, the same people cautioned. One of the people said listing the entity in Shanghai was also possible.
据三位知情人士透露，这家英瑞制药商几个月前开始与银行家们讨论这一想法，而且目前考虑这一选择的跨国公司越来越多，阿斯利康只是其中之一。
The discussion shows the significant restructuring multinational corporations could be forced to undertake as they adapt to growing friction between China and the US and its allies.
这些人士警告称，最终也可能不会分拆。其中一名知情人士表示，该实体也有可能在上海上市。
